Table 2.
Efficacy and effectiveness of the vaccines against SARS-CoV2 and its variants.
| Vaccine | Type | Efficacy/Effectiveness/Neutralisation |
||||||
|---|---|---|---|---|---|---|---|---|
| SARS-CoV-2 | B.1.1.7 | B.1.351 | P.1 | B.1.617.1 | B.1.617.2 | B.1.1.529 | ||
| CanSino Biologics Inc. (AD5-nCOV) | Viral vector | 57.5% against SC | Unknown | Unknown | Unknown | Unknown | Unknown | Unknown |
| Bharat (BBV152) | Inactivated virus | 77.8% for SC 93.4% for severe SC 63.6% for AC 68.8% for SC and AC |
Unknown | Unknown | Unknown | 90.1% | 65.2% | Unknown |
| Inovio Pharmaceuticals (INO-4800) | DNA | 70& for SC | 2.1-fold reduction | 6.9-fold reduction | Neutralisation equivalent to the original strain | Unknown | Unknown | Unknown |
| Pfizer/BioNTech (BNT162b2) | mRNA | 52.4% after FD 95.0% 7 d after SD |
49.2% after FD 87.0–93.4% 14 d after SD |
72.1–75.0% 14 d after SD | Neutralisation equivalent to the original strain | 6.8-fold reduction | 33.2% after FD 87.9% after SD |
35% |
| Moderna (mRNA-1273) | mRNA | 94.1% 14 d after SD | 1.2-fold reduction | 6.4-fold reduction | 3.5-fold reduction | 6.8-fold reduction | 55.6% after FD 60.7% after SD 94% after TD |
20% after FD 42.8% after SD 67.7% after TD |
| Novavax (NVX-CoV2373) | Protein Subunit | 89.7% (phase III UK) 89.3% (phase III US) |
86.3% (phase III trial UK) 93.6% (phase III trial US/Mexico) |
Unknown | Unknown | Unknown | Unknown | Unknown |
| Oxford/AstraZeneca (ChAdOx1) | Viral vector | 64.1% 21 d after FD 62.1–76.0% 15 d after SD |
51.4% after FD 66.1–70.4% after SD |
10.4% 15 d after SD | 2.9-fold reduction | Unknown | 32.9% after FD 59.8% after SD |
Unknown |
| J&J/Janssen (JNJ-78436735) | Viral vector | 66.9% 14 d after FD 66.1% 28 d after SD |
Unknown | 52.0% 14 d after FD 64.0% 28 d after FD |
66.2% 14 d after FD 68.1% 28 d after FD |
Unknown | Unknown | Unknown |
| Sinovac (CoronaVac) | Inactivated virus | 57.9% 14 d after FD 50.7% 14 d after SD |
2.9-fold reduction | 5.5-fold reduction | Single-dose wasn't effective 41.6% 14 d after SD 4.3-fold reduction |
Unknown | 3.4-fold reduction | 12.5-fold reduction |
| Sinopharm (WIV04 and HB02) | Inactivated virus | 72.8% after SD 78.1% after SD |
Unkown Unknown |
Unkown 10-fold reduction |
Unkown Unknown |
Unkown Unknown |
Unkown 1.38-fold reduction |
Unknown |
| Sputnik V (Gam-COVID-Vac) | Viral vector | 91.6% after SD | Unknown | 6.1-fold reduction | Unknown | Unknown | Unknown | Unknown |
D: days; FD: first dose; SD: second dose; TD: third dose; SC symptomatic case; AC asymptomatic case; *Reduction in neutralisation by sera from vaccinated individuals.